Autopsy report · NCT05581199

To Assess Efficacy and Safety of Batoclimab in Adult Participants With Active CIDP

Cause of deathFunding or business Automatic label, confidence 0.9, unverified. How labels are made.

“Sponsor Decision”

The sponsor’s own words in the registry.

Life of this trial

Registered 2 months before it started.
Ran for about 3 years 7 months before it stopped.
94 participants enrolled.
No results are posted on the registry.

Vital statistics

Status: Terminated
Phase: Phase 2
Sponsor: Immunovant Sciences GmbH
Sponsor type: Industry
Conditions: Chronic Inflammatory Demyelinating Polyneuropathy
Interventions: Batoclimab 680 milligrams (mg) subcutaneous (SC) weekly; Batoclimab 340 mg SC weekly; Placebo
Participants: 94
Sites: 98
Countries: Argentina, Belgium, Brazil, Bulgaria, Canada, Denmark, Finland, Germany, Greece, Italy, Norway, Poland and more

Look deeper

The official registry record (the source of truth)
Record history: every change the sponsor made
Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.